66 completed, 7 active not recruiting, 7 unknown, 5 withdrawn. 29 Phase 1, 25 Phase 2, 24 Not applicable, 13 Phase 4, 6 Phase 3.
Follow Glucagon: new trials by email Literature Review of Glucagon trials Research Report on Glucagon
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Human Models of Selective Insulin Resistance: Pancreatic Clamp Insulin human, Octreotide Acetate, Glucagon - Insulin Resistance, Hyperinsulinemia | Phase 1 | Not yet recruiting | Columbia University | 36 | 2027-01-01 | 2026-02-06 |
| Studies of Insulin and Glucagon Action in the Liver Glucagon, Saline (placebo) - Diabetes (DM) | Phase 1 / Phase 2 | Not yet recruiting | Duke University | 40 | 2026-10-01 | 2026-08-05 |
| The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance. Glucagon, Glucagon+Exendin9-39, Sodium chloride - Kidney Diseases | Not applicable | Not yet recruiting | Bispebjerg Hospital | 10 | 2026-06-01 | 2025-10-03 |
| The Postprandial Hypo-Avoid Study Low-Dose Glucagon, Glucose Arm - Type 1 Diabetes Mellitus | Phase 4 | Recruiting | Steno Diabetes Center Copenhagen | 18 | 2026-04-27 | 2026-08-13 |
| Post-Prandial Carbohydrate Metabolism in Individuals With and Without Post-Bariatric Surgery Hypoglycemia (PBH) Glucagon for Injection (Fresenius Kabi USA), [6,6-2H2] glucose, [13C9, 15N1]-glucagon - Hypoglycemia, Hypoglycemia, Reactive | Phase 4 | Recruiting | Joslin Diabetes Center | 40 | 2026-01-27 | 2026-09-14 |
| Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 Diabetes Glucagon, Glucose - PreDiabetes | Not applicable | Recruiting | Mayo Clinic | 60 | 2025-04-01 | 2026-04-20 |
| Investigating the Acute Effects of Increasing Glucagon Exposure in Healthy Participants Glucagon - Glucose Metabolism, Glucagon | Not applicable | Completed | Nicolai Jacob Wewer Albrechtsen | 16 | 2025-03-31 | 2025-12-24 |
| The Effect of Glucagon on Cerebral Glucose Metabolism in Healthy Humans Glucagon (part C), Glucose clamp (part C), Saline (part C) - Cerebral Glucose Metabolism | Not applicable | Active not recruiting | Nicolai Jacob Wewer Albrechtsen | 12 | 2025-03-18 | 2026-04-29 |
| Glucagon Dose-Response in Patients With Post-Bariatric Hypoglycemia Glucagon for Injection (Fresenius Kabi USA) - Hypoglycemia, Hypoglycemia, Reactive | Phase 4 | Active not recruiting | Joslin Diabetes Center | 28 | 2024-11-26 | 2026-02-06 |
| Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PET 18F-FDG (oral), 18F-FDG (intravenous), 18F-FET (oral) - Glucose Metabolism, NAFLD (Nonalcoholic Fatty Liver Disease) | Not applicable | Active not recruiting | Copenhagen University Hospital, Rigshospitalet | 36 | 2024-11-05 | 2026-02-02 |
| Graded Insulin Suppression Test P&F Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia), Insulin regular, 32 mU/m2/min (hyperinsulinemia), Octreotide Acetate, 6-45 ng/kg/min - Insulin Resistance, Hyperinsulinemia | Phase 1 | Completed | Columbia University | 20 | 2024-09-16 | 2026-10-16 |
| Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents Dasiglucagon, Glucagon - Diabetes Mellitus, Type 1 | Phase 1 | Completed | Novo Nordisk A/S | 38 | 2024-09-10 | 2025-12-05 |
| Dexamethasone/Pancreatic Clamp P&F Insulin human, Octreotide Acetate, Glucagon - Insulin Resistance, Prediabetic State | Phase 1 | Withdrawn | Columbia University | 2024-07-01 | 2024-07-10 | |
| The Underlying Mechanisms Regarding the Effect of Glucagon on the Kidneys Will be Investigated in Healthy Males. Glucagon, Placebo, Glucagon and exendin 9-39 - Kidney Diseases | Not applicable | Unknown | Ali Asmar | 10 | 2024-02-20 | 2024-07-12 |
| Glucagon Enhanced Insulin Absorption in Diabetes Mellitus Type 1 Glucagon - Type 1 Diabetes | Phase 2 | Terminated | St. Olavs Hospital | 9 | 2023-12-22 | 2025-06-13 |
| Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer. Radiotracer Injection, Contrast Media, Magnetic Resonance, Blood Draw - Crohn Disease | Recruiting | Massachusetts General Hospital | 25 | 2023-12-19 | 2026-03-12 | |
| Pancreatic Clamp in NAFLD Insulin human, Octreotide Acetate, Glucagon - Insulin Resistance, Prediabetic State | Phase 1 | Completed | Columbia University | 18 | 2023-08-29 | 2026-01-12 |
| The Effects of Glucagon on Hepatic Metabolism Glucagon response study - Obesity, Type2diabetes | Phase 1 / Phase 2 | Completed | Adrian Vella | 21 | 2022-10-20 | 2026-10-14 |
| Glucagon and Advanced HCL System to Prevent Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes GlucaGen - Type 1 Diabetes, Hypoglycemia | Not applicable | Completed | Steno Diabetes Center Copenhagen | 10 | 2022-09-21 | 2025-08-29 |
| Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes 0.9% Sodium-chloride, Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min, Glucagon 12.5ng/kg/min and 0.9% saline - Type 2 Diabetes, Obesity | Phase 4 | Completed | Cambridge University Hospitals NHS Foundation Trust | 10 | 2022-01-18 | 2024-09-19 |
Showing 20 of 96. Sign in to see all of them.
Diabetes Mellitus, Type 1 (39) · Hypoglycemia (31) · Insulin Resistance (18) · Diabetes Mellitus (16) · Obesity (10) · Non-alcoholic Fatty Liver Disease (8) · Diabetes Mellitus, Type 2 (7) · Hyperinsulinism (4) · Prediabetic State (4) · Glucose Metabolism Disorders (3) · Motor Activity (3) · Congenital Hyperinsulinism (2) · Endocrine System Diseases (2) · Hyperglycemia (2) · Kidney Diseases (2)
Xeris Pharmaceuticals (10) · Institut de Recherches Cliniques de Montreal (6) · Steno Diabetes Center Copenhagen (6) · Columbia University (4) · Eli Lilly and Company (4) · Massachusetts General Hospital (4) · Zealand Pharma (4) · AdventHealth Translational Research Institute (3) · Joslin Diabetes Center (3) · Legacy Health System (3) · Cambridge University Hospitals NHS Foundation Trust (2) · Jaeb Center for Health Research (2) · Nicolai Jacob Wewer Albrechtsen (2) · Novo Nordisk A/S (2) · Sanofi (2)
United States (49) · Denmark (16) · Canada (13) · Germany (8) · United Kingdom (2) · Australia (1) · Austria (1) · Belgium (1) · Israel (1) · Japan (1) · Norway (1) · Saudi Arabia (1) · Switzerland (1) · Taiwan (1)
Joshua R Cook, MD, PhD (3) · Steven J Russell, MD, PhD (3) · David D'Alessio, MD (2) · Lauren Sparks, PhD (2) · Morey W Haymond, MD (2) · Nicolai J Wewer Albrecthsen, MD PhD (2) · Sissel B Lundemose, MD (2) · W Kenneth Ward, MD (2) · Adrian Vella (1) · Adrian Vella, MD (1) · Agneta L. Sunehag (1) · Ajenthen G Ranjan, MD, PhD (1)
PMID 34620618, PMID 15793249, PMID 24168317, PMID 26341131, PMID 26861921, PMID 28591776, PMID 29273578, PMID 29355439, PMID 29776987, PMID 33006765, PMID 33103603, PMID 34029448, PMID 35176134, PMID 35322535, PMID 35994729, PMID 36001750, PMID 37967235, PMID 38427076, PMID 39291967, PMID 41699282, PMID 42866259
P30DK063608 (3), 2016 (2), 2019 (2), R01DK137518 (2), R44DK107114 (2), 2005 (1), 2014 (1), K12DK133995 (1), R01DK101991 (1), R01DK116231 (1), R01DK141090 (1), R44DK096715 (1), R44DK105691 (1), U24DK100469 (1)